Table 4.
Odds Ratio of Recombinant Zoster Vaccination Among Severe Acute Respiratory Syndrome Coronavirus 2 Test-Positive Cases Versus Test-Negative Controls
| Exposure | Test Positive (n = 75 726) | Test Negative (n = 340 898) | Odds Ratio (95% CI) | |||
|---|---|---|---|---|---|---|
| No. | (%) | No. | (%) | Unadjusted | Adjusteda | |
| RZV (≥1 dose) vaccinated | 6392 | (8.4) | 44 786 | (13.1) | 0.61 (.59–.63) | 0.84 (.81–.86) |
| 15 days to <1 monthb | 302 | (0.4) | 1810 | (0.5) | 0.71 (.63–.81) | 0.79 (.69–.90) |
| 1 to <6 months | 1703 | (2.3) | 10 643 | (3.1) | 0.68 (.65–.72) | 0.87 (.82–.92) |
| 6 months to <1 year | 1697 | (2.2) | 14 606 | (4.3) | 0.50 (.47–.52) | 0.83 (.78–.87) |
| ≥1 year | 2690 | (3.6) | 17 727 | (5.2) | 0.65 (.62–.68) | 0.82 (.79–.86) |
| RZV (2 doses) vaccinated | 4108 | (5.4) | 31 359 | (9.2) | 0.56 (.54–.58) | 0.82 (.79–.85) |
| RZV unvaccinated | 69 334 | (91.6) | 296 112 | (86.9) | NA | NA |
Abbreviation: CI, confidence interval; NA, not applicable; RZV, recombinant zoster vaccine; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
Adjusted for the following covariates: age, sex, race/ethnicity, calendar time, body mass index, smoking, number of outpatient visits, number of emergency department visits, frailty, cardiovascular disease, hypertension, pulmonary disease, renal disease, cancer, other vaccinations, and medical center area.
Time since most recent RZV vaccination.